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abstract. In recent years, Indonesia has facing with the increase in population size alongside with the increase in
people’s life expectation as one of the effect of people’s awareness in healthy life. Pharmaceutical industry in
Indonesia is said to be having a positive growth with this condition therefore PT Kimia Farma Tbk, as the first
pharmaceutical company in Indonesia does have an increase for its sales but unexpectedly it has a decrease for its
net profit margin in 2013. Financial performance assessment will be done in order to know the real condition of PT
Kimia Farma Tbk’s financial condition and it will also be compared with local and regional companies so that the
result becomes clearer. The analysis method includes financial ratios analysis, DuPont analysis, BUMN
framework, and Moody’s framework. The result of the assessment in 2010 - 2014 shows that PT Kimia Farma Tbk
has a good financial condition but it still need to be improved with some suggestions based on the financial
assessment.
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Introduction
In recent years, Indonesia as a developing country has facing with many different conditions and
high population size is one of them. Indonesia’s population size is keep increasing in each year with
up to 1.2% of growth and this phenomenon is happened alongside with the increase in people’s life
expectancy. One of the causes of the increase in life expectancy is the enhancing in people’s
awareness in healthy living. With this healthy issue, pharmaceutical industry is said to be having a
positive growth as well. In Indonesia, there are some top companies that run the business in
pharmaceutical industry and one of them has doing the business for more than ten decades, which is
PT Kimia Farma Tbk. Following the current situation in which pharmaceutical industry has been
showing a promising prospect, PT Kimia Farma Tbk is supposed to be having a positive growth in
each year. In reality, PT Kimia Farma Tbk’s sales do increase but it also stated that its net profit
margin has decreases in 2013. This makes it interesting to know about the real condition of PT Kimia
Farma Tbk’s financial performance in recent years. To make the financial performance assessment
clearer, PT Kimia Farma Tbk will be compared with its local and regional benchmarks, which are PT
Kalbe Farma Tbk, PT Indofarma Tbk, Eu Yan Sang International Limited, and Apex
Healthcare Berhad.Therefore, the research questions of this paper are:
1. How is the financial performance of PT Kimia Farma Tbk if compared to the other local
and regional pharmaceutical companies?
2. How is the financial condition of PT Kimia Farma Tbk as a stated-owned company
(BUMN) based on The Ministry of BUMN Indonesia regulation?
3. How is the financial performance of PT Kimia Farma Tbk based on an international
standard rating method?
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4. Is there any recommendation that can be given in order to improve PT Kimia Farma
Tbk’s financial performance?
Literature Review
Financial Statement
Financial statement is a written report that shows company’s financial performance in particular
periods of time, usually for one-year period. Financial statement are made to show the readers
about the financial information as concisely and clearly as possible so it would be useful for both
the stockholders and the management of the company itself. There are four key of financial
statements which are; (1) Income Statement, (2) Balance Sheet, (3) Statement of Stockholders’
Equity, and (4) Statement of Cash Flow.
Financial Ratios
In finance, there are several ratios that can be used to see how well is the performance of a
company in some sorts of years that have been chosen. After the ratios are calculated by using
some data from financial statement of the company, these ratios can be compared and analyzed
with the other company’s financial ratios. There are several types of financial ratios, which are:
 Liquidity ratios: Current ratio and quick ratio
 Activity ratios: Inventory turnover, average collection period, average payment period, and
total asset turnover
 Debt ratios: Debt ratio and times interest earned ratio
 Profitability ratios: Gross profit margin, operating profit margin, net profit margin, earnings
per share, return on total asset, and return on total equity
 Market ratios: Price/earnings ratio
Cross-Sectional Analysis
After done with calculating the financial ratios, now the data can be compared using some
analytical methods and the first one is Cross-Sectional Analysis. With this method, the company
can compare its financial ratios with the other companies.
Trend Analysis
The other analytical method that can be used to compare company’s financial ratios is Trend
Analysis. With this analytical method, the company or investors can compare the financial ratios
of a company from period A with period B, C, D, etc. and the result will show about the
comparison between the financial conditions of the company from period to period based on its
financial ratios.
Growth Rate Comparison
Growth rate comparison is a method that use the compound annual growth return (CAGR)
calculation to find out about company’s growth in a chosen range of time.
DuPont System of Analysis
DuPont system of analysis is a method that was started by the DuPont Corporation in the 1920s
and being used until today. This method basically breaks up ROA and ROE into some
components so the actual performance of the company can be seen clearer.
Badan Usaha Milik Negara (BUMN) Framework
BUMN that stands for Badan Usaha Milik Negara, is the company or business entity
owned by the government of a country. In this case, it is the company that owned by
Indonesia’s government. The Ministry of BUMN Indonesia has a scoring method or
framework that being used to give a score for the BUMN based on their performances. ,
There are some aspects that can be seen as the indicators, which can be seen in the table
below together with the maximum score a company can get for each of the indicator.
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Moody’s Rating Methodology (Moody’s Framework)
Moody’s Investors Service or commonly known as Moody’s Framework is the part of Moody’s
Corporation that provides services such as rating methodology that includes assessing credit risk
for companies. For the rating methodology, Moody’s has already separated it into some sections
based on the type of the business and pharmaceutical industry is one of them. With Moody’s
rating methodology, it may gives information that helps companies, investors, and other
interested market participants to understand how key qualitative and quantitative risk
characteristics are likely to affect rating outcomes for companies in the pharmaceutical industry.
In Moody’s rating methodology, to asses global companies in the pharmaceutical industry based
on its financial performance, there are three rating factors that can be used.
No. Rating Factors Rating Sub-Factors
1 Scale (25%) Revenue (25%)
2 Leverage and Cash Coverag (24%) Debt To EBITDA (9%)
Cash Flow from Operation to Debt (9%)
Pharmaceutical Cash Coverage (6%)
3 Financial Policy (10%) -
Total = 59%
Methodology
For the methodological step in this research, below is the flow chart that shows how this research
will be done.
No. Indicator Score
1 ROE 20
2 ROI 15
3 Cash Ratio 5
4 Current Ratio 5
5 Collection Periods 5
6 Inventory Turnover 5
7 Total Asset Turnover 5
8 Equity to Total Asset Ratio 10
Total Score 70
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Data Analysis
Trend Analysis
Trend analysis compares each of the company’s financial ratios over time period, which will give
information about which are the strongest or the weakness year for the companies. The financial
ratios of Kimia Farma can be seen in table below:
Liquidity
In liquidity ratio, there are two basic measures, which are current and quick ratio. Kimia Farma
shows a stable in both current and quick ratio with a little increase in year 2010 - 2012 but then
declines in 2013 - 2014. Overall, it means that Kimia Farma’s ability in meet its short term obligation
KAEF
Ratios
Liquidity
Current ratio
Quick ratio
Activity
Inventory turnover
Average collection period
Average payment period
Total assets turnover
Debt
Debt ratio
Times interest earned ratio
Profitability
Gross profit margin
Operating profit margin
Net profit margin
Earnings per share (EPS)
Return on total assets (ROA)
Return on common equity (ROE)
Market
Price earning ratio (P/E Ratio)
2010 2011 2012 2013 2014
2.42548712 2.74754265 2.80313215 2.42669674 2.38699459
1.60250938 1.75542962 1.8157292 1.56771071 1.58283281
5.89496634 5.35697893 4.82464303 4.76810316 4.56140664
41.0087103 40.26623 44.8380015 45.8824747 41.5723345
68.8556061 60.6626399 69.5081515 81.5421393 84.0158906
1.9211036 1.94001732 1.79846628 1.75897262 1.52316144
0.32779832 0.30190417 0.30573585 0.34288252 0.38981425
10.8337832 19.626075 41.4835893 31.3422907 12.7583916
28.41% 29.82% 31.47% 29.72% 30.65%
4.59% 6.38% 7.57% 6.67% 7.41%
4.36% 4.93% 5.49% 4.93% 5.19%
24.98 30.93 36.93 38.63 42.24
8.37% 9.57% 9.88% 8.68% 7.90%
12.45% 13.71% 14.23% 13.21% 12.95%
5.89111289 10.5929518 19.0433252 15.0012943 34.4415246
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has decrease in recent five years but Kimia Farma still can fulfill its obligations since the ratio is
positive.
Activity
Activity ratio includes inventory turnover, average collection period, average payment period, and
total asset turnover. Basically, activity ratios may give information about company’s efficiency in
managing several things, such as inventory, collections, etc. Kimia Farma’s inventory turnover keep
decreasing from 2010 – 2014, which means its inventory has becoming less liquid for the last five
years.
Debt
In debt, there are two ratios that being used to asses the company’s performance. The first one is
debt ratio that calculates company’s proportion of its total asset that being financed by creditors.
Kimia Farma shows a pretty constant result in recent five years, which is around 30% means that
30% of Kimia Farma’s total asset is being financed by its debt or liabilities.
Profitability
Profitability ratio is being used to assess company’s ability in generating profit compared to its
several cost for the business. Some measurements for profitability ratio includes gross profit
margin, net profit margin, earnings per share (EPS), return on asset (ROA), and return on equity
(ROE). In terms of profitability, Kimia Farma always give a positive value, which is good. For gross
profit margin, operating profit margin, and net profit margin, the trend is also positive in year 2010 –
2012, although it has decreased in 2013, but Kimia Farma succeed to fix it in 2014. Kimia Farma’s
EPS is also keep increasing from 2010 – 2014.
Market
For market ratio, company’s performance can be seen based on its price earning (P/E ratio.) This
ratio can shows investor’s confidence towards the company, so it will be better to have a high result.
Kimia Farma shows a good trend, which is increasing from 2010 – 2012, decrease in 2013, but then
succeed in manage its performance so it reaches the highest result in 2014.
4.2 Growth Rate Comparison
To analyze the growth rate, the method that being used is compound annual growth rate (CAGR)
which measures how are these five pharmaceutical companies’ performance based on the growth of
their financial ratios from 2010 to 2014. The result for the five companies’ CAGR can be seen in table
below:
Based on the table above, it can be seen that for liquidity, Apex is the only one with positive
growth both in current and quick ratio. It means that Apex can maintain its ability in fulfilling its
obligation for the recent five years while the other four companies show a negative growth,
which means their ability diminish. Kalbe Farma has the worst growth for its liquidity ratio as an
CAGR KAEF KLBF INAF EYS Apex
Ratios
Liquidity
Current ratio -0.32% -4.96% -3.43% -3.68% 0.18%
Quick ratio -0.25% -7.03% -3.52% -8.73% 1.60%
Activity
Inventory turnover -5.00% -2.48% 1.52% -3.98% 4.61%
Average collection period 0.27% 1.82% 3.21% -1.01% -1.05%
Average payment period 4.06% 5.72% -0.33% -3.99% 1.13%
Total assets turnover -4.54% -0.79% -4.97% -5.47% 3.61%
-1.30% 1.07% -0.14% -3.61% 2.08%
Debt
Debt ratio 3.53% 3.21% -1.80% 7.16% 0.88%
Times interest earned ratio 3.32% -8.78% -12.27% -33.88% 130.96%
Profitability
Gross profit margin 1.53% -0.69% -5.74% -0.22% -2.66%
Operating profit margin 10.06% -1.37% -9.04% -5.46% -1.25%
Net profit margin 3.56% -1.12% -41.16% -12.16% -8.37%
Earnings per share (EPS) 11.08% -20.32% -49.81% -5.27% -3.83%
Return on total assets (ROA) -1.14% -1.90% -44.09% -16.96% -5.06%
Return on common equity (ROE) 0.79% -1.15% -45.32% -11.75% -4.76%
Market
Price earning ratio (P/E Ratio) 42.36% 62.89% 168.67% 4.72% 19.25%
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effect of the high amount of current liabilities that is not followed by a high increase in its
current asset.
For the activity, Kimia Farma has the worst growth for its inventory turnover but it has a good
improvement for its average payment period. Eu Yan Sang has negative growth for its entire
activity ratio, shows that it performance has declined in 2014 compared to the earlier year,
which is 2010.
For the debt, Kimia Farma has positive growth for both of its debt ratio means that Kimia Farma
has a higher leverage in 2014 but it also able to fulfill its interest payments better in 2014. Apex
has a really high growth for its times interest ratio that caused by its small interest payment in
2014. For the profitability, overall Indofarma has the worst performance compared to the
others. This happened because Indofarma has a loss for its income in 2013 and so in 2014, it has
not full recovery yet although it succeeds in gaining profit, but it is not as big as what Indofarma
earned in the previous years. Seems like Indonesia’s bad economy condition in 2013 has
damaged Indofarma quite much. On the other hand, Kimia Farma has the best result overall
among the rest of the companies because most of its profitability ratios are showing positive
growth except for its ROA but it does not really matter. It means that the decrease in Kimia
Farma’s net profit margin in 2013 does not really give bad impact because Kimia Farma succeeds
in increasing it profit margin that turns out it has a good growth in recent five years.
4.3 Cross Section Analysis
Cross section analysis can be used to compare the financial performance from all of the
companies based on their financial ratios in a period of time. The result of the five companies’
financial ratios in 2014 can be seen in table below:
In 2014, overall Kalbe Farma shows the best performance while Indofarma shows the worst. For
current and quick ratio, all of the companies have good results but it seems like it is not good
enough for Indofarma and Eu Yan Sang because their scores are lower than the average of the
five companies. Kimia Farma shows a pretty good result compared to the average and also it has
the best total assets turnover among the other four companies and the average. Eu Yan Sang
has two lowest scores, which are inventory turnover and total asset turnover, but it also has two
highest scores, which are average collection and payment period. For profitability ratio, Kimia
Farma and Apex show good result but if compared to the average, Kimia Farma only has three
aspects those are better than the average, which are EPS, ROA, and ROE. Otherwise, most of
the aspects in profitability of Apex are better than the average except for its gross profit margin.
2014 Average KAEF KLBF INAF EYS Apex
Ratios
Liquidity:
Current ratio 2.20545772 2.38699459 3.40363666 1.30358391 1.39794594 2.53512752
Quick ratio 1.43939454 1.58283281 2.10831078 0.94324544 0.60994628 1.95263738
Activity
Inventory turnover 4.39553391 4.56140664 2.87740183 4.93981693 2.18820262 7.41084153
Average collection period 47.007189 41.5723345 49.3210599 51.9130765 11.9814097 80.2480645
Average payment period 88.1104865 84.0158906 66.4392689 163.248049 41.0822511 85.7669736
Total assets turnover 1.29672809 1.52316144 1.39786618 1.10661595 1.04745277 1.40854411
Debt
Debt ratio 0.38795969 0.38981425 0.20986317 0.52580095 0.54870251 0.26561759
Times interest earned ratio 18.0501615 12.7583916 52.9711289 1.31289998 5.15822551 5449.91262
Profitability
Gross profit margin 35.13% 30.65% 48.80% 22.62% 50.31% 23.26%
Operating profit margin 8.60% 7.41% 15.86% 3.35% 7.62% 8.77%
Net profit margin 5.61% 5.19% 11.89% 0.08% 4.10% 6.78%
Earnings per share (EPS) 23.782 42.24 44 0.38 3.38 28.91
Return on total assets (ROA) 7.69% 7.90% 16.62% 0.09% 4.30% 9.55%
Return on common equity (ROE) 11.34% 12.95% 21.03% 0.20% 9.53% 13.01%
Market
Price earning ratio (P/E Ratio) 18.9854134 34.4415246 41.1590909 934.210526 0.21893491 0.12210308
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DuPont System of Analysis
The calculation using DuPont Analysis will be resulted in the breaks parts of ROA and ROE of the
five companies. The result of DuPont analysis in 2014 can be seen in table below:
Operating Efficiency
The company’s operating efficiency can be seen based on its net profit margin. Overall, the
trend is the pretty similar, which are increase in 2011 and 2012 except for Apex, and then
decrease in 2013, and then decrease again in 2014 except for Kimia Farma and Indofarma.
Asset-Use Efficiency
In DuPont analysis, asset-use efficiency can be seen based on company’s total asset turnover. All
of the company show different trend for their asset-use efficiency. Overall, Kimia Farma has the
best total asset turnover with its highest score in 2012 but then decrease until 2014. This means
that Kimia Farma’s ability in generating sales from its asset is getting worse since 2012 – 2014.
Financial Leverage
To see company’s financial leverage condition, in DuPont analysis it can be done by calculating
company’s equity multiplier, which is dividing total asset with total equity. All of the company
shows unpredictable and fluctuated trends with pretty stable growth for Apex, Kimia Farma,
and Kalbe Farma while Indofarma and Eu Yan Sang have bigger increase in 2013. The condition
of company’s equity multiplier can show how does the company manage to finance its asset,
whether by using equity or debt.
BUMN Framework
BUMN Framework is a method from The Ministry of BUMN in Indonesia that being used to asses
the performance of Indonesia’s stated owned company (BUMN).
Here are the results of BUMN framework assessment for the five companies:
2014 KAEF KLBF INAF EYS Apex
Net profit margin
0.05189657
5 0.118875136 0.000844102
0.04104382
9 0.067832009
Total asset
turnover
1.52316144
3 1.397866181 1.106615949 1.04745277 1.408544111
Equity multiplier
1.63884523
2 1.26560358 2.108819081
2.21583326
5 1.361688389
ROA 7.90% 16.62% 0.09% 4.30% 9.55%
ROE 12.95% 21.03% 0.20% 9.53% 13.01%
Result Score Result Score Result Score
Indicators:
ROE 13.06% 18 21.61% 20 0.20% 2
ROI 14.45% 12 32.64% 15 6.13% 5
Cash ratio 67.07% 5 79.41% 5 22.60% 3
Current ratio 238.70% 5 340% 5 130% 5
Collection periods 41.572 5 49.321 5 51.913 5
Inventory turnover 55.497 5 64.948 5 57.179 5
Total asset turnover 187.58% 5 192.54% 5 162% 5
Equity to total asset ratio 61.02% 8 79.01% 7.5 47.42% 9
Rank
63 67.5 39
AA AAA BBB
3 1 5
Result
2014 Kimia Farma Kalbe Farma Indofarma
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Kimia Farma is ranked on the third place but actually its score only lost for 0.5 point from Apex,
which is ranked on the second place. Apex is better for the efficiency in gaining profits from its
investment while Kimia Farma is better at collecting its receivables and also it has a better
proportion for its total asset and total equity. But a good ROI is more important for a company to be
categorized as a healthy company based on the regulation from The Ministry of BUMN and that is
why Apex got higher score even though Kimia Farma is better at two indicators.
Moody’s Rating Methodology
Moody’s framework provides different types of rating methodology based on the industry of the
company and rating methodology for pharmaceutical company is one of them. The score and rate
for each of the companies can be seen in the following tables:
In the first rating factor, which is leverage and cash coverage, there are three sub-factors, which are
debt to EBITDA, cash flow from operation to debt, and pharmaceutical cash coverage of debt. For
debt to EBITDA, Kimia Farma got the third place, which is good enough, and Kalbe Farma got the
first place followed by Apex. Indofarma and Eu Yan Sang have the same rate and apparently Ca is
the worst rate for this rating factor. For cash flow from operation to debt factor, Kalbe Farma once
again got the first place followed by Apex, Kimia Farma and Indofarma, and Eu Yan Sang on the last
place again. This factor indicates company’s financial flexibility in paying its debt and also shows the
amount of cash flow available for capital expenditure and external growth opportunities. For
pharmaceutical cash coverage of debt, none of the five companies shows a very bad result. Kimia
Result Score Result Score
Indicators:
ROE 9.60% 14 13.05% 18
ROI 16.51% 13.5 17.23% 13.5
Cash ratio 42.75% 5 41.14% 5
Current ratio 140% 5 254% 5
Collection periods 11.981 5 83.208 4.5
Inventory turnover 82.883 4.5 37.797 5
Total asset turnover 156% 5 196% 5
Equity to total asset ratio 45.13% 9 73.44% 7.5
Rank 4 2
61 63.5
2014
Result
Eu Yan Sang Apex
AA AA
Pharmaceutical
Companies
Grid
Indicated
Rating
Score WeightedScore
Grid
Indicated
Rating
Score WeightedScore
Grid
Indicated
Rating
Score WeightedScore
Kimia Farma Ba 7.08 0.6372 Ba 7.08 0.6372 Aa 1.77 0.1062
Kalbe Farma Aa 1.77 0.1593 Aaa 0.59 0.0531 Aa 1.77 0.1062
Indofarma Ca 11.8 1.062 Ba 7.08 0.6372 Ba 7.08 0.4248
Eu Yan Sang Ca 11.8 1.062 Caa 10.62 0.9558 Aa 1.77 0.1062
Apex Baa 5.31 0.4779 Baa 5.31 0.4779 B 8.85 0.531
Debt to EBITDA
Leverage and Cash Coverage
Cash Flow from
Operation to Debt
Pharmaceutical Cash
Coverage of Debt
Pharmaceutical
Companies
Grid
Indicated
Rating
Score WeightedScore
Grid
Indicated
Rating
Score WeightedScore
Kimia Farma Ca 11.8 2.95 A 3.54 0.354
Kalbe Farma B 8.85 2.2125 Aa 1.77 0.177
Indofarma Ca 11.8 2.95 Caa 10.62 1.062
Eu Yan Sang Ca 11.8 2.95 Baa 5.31 0.531
Apex Ca 11.8 2.95 A 3.54 0.354
Revenue
Scale Financial Policy
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Farma, Kalbe Farma, and Eu Yan Sang have the best performance compared to others, followed by
Indofarma, and then Apex. This factor can give information about company’s financial flexibility and
the ability to absorb unpredicted events or make strategic acquisitions. It means Kimia Farma has
succeed in manage its cash from debt so that it has more than enough reserved cash that can be
used to finance unpredicted events.
The next factors is revenue, which is the sub-factor in indicating company’s scale and based on the
Moody’s standard, Kimia Farma has a very bad revenue as well as the other companies except for
Kalbe Farma. This situation might happened because of Moody’s criterion that uses US dollar as its
standard and so Kalbe Farma is the only one that can get a quite good rate because it has the
highest revenue in 2014 compared to the other benchmarking companies. The last factor is financial
policy that assesses company’s overall financial performance in that year. Kimia Farma got a good
result for this factor as well as Apex that got same score and Kalbe Farma that got higher result.
Here is the final result from the assessment in table below:
Pharmaceutical
Companies Score
Aggregate
Weighted
Factor Score
Indicated
Rating Rank
Kimia Farma 4.6846 4.425≤ x < 5.015 Baa1 2
Kalbe Farma 2.7081 2.655 ≤ x < 3.245 A1 1
Indofarma 6.136 5.605 ≤ x < 6.195 Baa3 5
Eu Yan Sang 5.605 5.605 ≤ x < 6.195 Baa3 4
Apex 4.7908 4.425≤ x < 5.015 Baa1 3
After calculating all of the weighted score, companies’ final rate result and rank can be seen. A lower
final score will be better for the company’s indicated rating. Kimia Farma is on the second place after
Kalbe Farma, and followed by Apex, which has the same indicated rating but bigger score.
Conclusion
Conclusion
This part of the research will be divided into three parts based on the research questions and the
analytical method that has been used in order to conclude the overall analysis result.
Financial Performance of PT Kimia Farma Tbk in 2010 – 2014
Based on some financial ratios analytical methods that have been used, overall it shows that in 2010
– 2014, Kimia Farma has done well. Though it is not the best among the other benchmark
companies, but still it is above the average of the five companies. Kimia Farma shows its strength in
total asset turnover, ROE, and P/E ratio. Kimia Farma also dhas the best growth for profitability ratio
with a positive growth for almost all of the indicators, except for its ROA but it is still good because
its benchmark have negative trend.
Financial condition of PT Kimia Farma Tbk as a stated-owned company (BUMN) based on The Ministry
of BUMN Indonesia scoring method
Based on the assessment using the regulation from The Ministry of BUMN Indonesia, it shows that
in 2014, Kimia Farma has succeed to be a financially-healthy BUMN company with a final score of
AA. With total of eight indicators, Kimia Farma has reach the best score for cash ratio, current ratio,
collection periods, inventory turnover, and total asset turnover. But it does not really matters since
based on BUMN framework, those five indicators are not too important because its highest score is
not even that high (only 5.) The strength that Kimia Farma has and really help its scoring for this
framework comes from its high ROE and ROI, which get score of 18 out of 20 and 12 out of 15. It
means that Kimia Farma has succeed in fulfilling all of the criteria in being a healthy company.
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Financial performance of PT Kimia Farma Tbk based on an international standard rating method
Moody’s framework has been chosen as the international rating method that used to answer this
research question. Based on the assessment using Moody’s framework, Kimia Farma got the second
place if compared to its benchmark, and got Baa1 as its final rate. This final rate is pretty good
because Baa1 is ranked the seventh out of seventeenth. Kimia Farma shows its strength in some
factors, which are financial cash coverage and financial policy. This results shows that in 2014, Kimia
Farma has a good proportion of debt for its cash and investments and also it has an overall good
financial policy in that year. Since Moody’s framework is an international rating method, it means
that based on Kimia Farma’s financial performance in 2014, Kimia Farma is compatible in
international pharmaceutical industry.
Recommendation
Based on the conclusion above, some recommendations that can be given in order to improve Kimia
Farma’s financial performance are:
Managing cost of goods sold (COGS)
It seems like Kimia Farma’s sales has increase in each year but its COGS has also increase with
higher growth, resulted in decrease for its profitability ratios in 2013 and though it has improved in
2014, it is not better than in 2012. It is better to have a higher increase in sales than its COGS so that
the profitability ratio will have a positive growth.
Managing other cost and expenses
Not only COGS, Kimia Farma also faced with the increase in its cost and expenses, such as operating
expense and financial cost. This can be overcome by reducing the cost and expenses, for instance
decrease salaries and employees’ welfare and also amortization, electricity, fuel, water, and gas
payments. Maybe those cost and expenses cannot be reduced that much since for electricity, fuel,
etc, they are controlled by the government. As a solution, Kimia Farma can manage these cost and
expenses better so that the proportion of increase for its cost and expenses will not be higher than
the proportion of increase for its sales revenue because if not, the profitability will be decrease
though its sales revenue is increase.
Improve operating efficiency
Based on DuPont analysis in the previous chapter, it can be seen that Kimia Farma has a poor ability
in managing its operating efficiency compared to its benchmark. If Kimia Farma can improve its
operating efficiency, which means it needs to increase its net profit margin, it may be resulted in
higher ROA and ROE. Related to the previous recommendation, Kimia Farma needs to have a higher
proportion of increase for its earnings available for common stockholder than the increase for its
cost and expenses.
